Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer

Vogl, Thomas J.; Naguib, N; Nour-Eldin, Nour-Eldin A.; Eichler, Katrin; Zangos, S; Gruber‐Rouh, Tatjana

doi:10.1007/s00330-009-1525-0

Cited by 55 publications

(31 citation statements)

References 42 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, the treatment outcome of TACE was evaluated for BCLM; patients treated with TACE had higher response rates and better survival (Li et al 2005;Schneebaum et al 1994;Vogl et al 2010). Li et al (2005) compared results of TACE (n = 28) and systemic chemotherapy (n = 20) and concluded that there was statistically significant differences between the two groups in terms of response rates and survival rates.…”

Section: Discussionmentioning

confidence: 97%

“…Recently, minimally invasive therapy methods such as radiofrequency ablation (RFA), laser-induced thermotherapy (LITT) and transarterial chemoembolization (TACE) have been used for effective and relatively simple treatment of liver metastases from breast cancer (Jakobs et al 2009;Mack et al 2004;Vogl et al 2010;Gadaleta and Ranieri 2010). TACE is a local, catheter-based, minimally invasive therapeutic option for unresectable liver tumors and is defined as a selective administration of chemotherapy usually combined with embolization of the vascular supply of the tumor (Vogl et al 2010).…”

Section: Introductionmentioning

confidence: 99%

“…TACE is a local, catheter-based, minimally invasive therapeutic option for unresectable liver tumors and is defined as a selective administration of chemotherapy usually combined with embolization of the vascular supply of the tumor (Vogl et al 2010).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis

Duan

Dong

Zhang

et al. 2011

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis

Duan

Dong

Zhang

et al. 2011

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…With surgery, the OS rate is 49-75/41-61% at 3/5 years, respectively, with a median of 3.8-5.3 years (20-24). With TACE, the OS rate was 63-76/13-48% at 1/3 years, respectively (25)(26)(27) (Table II). Although severe adverse effects are rare, Caralt et al reported that 2/12 patients (17%) suffered from bile leakage postoperatively (28).…”

Section: Discussionmentioning

confidence: 99%

Follow-up study of liver metastasis from breast cancer treated by proton beam therapy

Fukumitsu

Okumura

Numajiri

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Liver metastasis from breast cancer (LMBC) is an incurable, fatal disease with a very poor prognosis. Although various local treatments have been applied, their clinical utility has not been established. The purpose of this study was to investigate the safety and effectiveness of proton beam therapy (PBT) for the treatment of patients with LMGC. A total of 8 female patients (aged 38-63 years) with LMBC who received PBT between 2002 and 2012 were retrospectively reviewed. Patients who had tumors confined to the liver were investigated, whereas patients with extrahepatic tumors were excluded. A total of 5 patients had solitary tumors and 3 had multiple tumors. The total irradiation dose was 66-72.6 Gray equivalent [Gy relative biological effectiveness (RBE)] and 2 patients received concurrent chemotherapy or hormone therapy. The overall and progression-free survival (OS and PFS) rates, local control (LC) rate and adverse effects were investigated. All the patients completed treatment without interruption and late adverse effects of grade >3 were not observed. The OS rate was 88/73/58%, the PFS rate was 50/25/0% and the LC rate was 86/86/86% at 1/3/5 years, respectively. Thus, PBT is a safe treatment and the OS and PFS rates are comparable to those with other local treatments. PBT may be considered as an effective local treatment option for the treatment of LMBC patients. IntroductionApproximately 50% of breast cancer patients will develop distant metastasis (1,2), which is a major cause of cancer-related mortality among women (3). In most series, isolated liver metastases are found in 5-25% of the cases (1,2,4-6). As the majority of LMBC patients may have systemic disease, only a limited number of patients are candidates for local treatment.Although systemic chemotherapy regimens with new molecular-targeted agents have been developed, LMBC is an incurable, fatal disease, with a median survival of 3-15 months (5,7,8) and the management of liver metastases remains challenging. Thus, the treatment of patients with LMBC is considered as palliative. To improve the treatment outcome, various local treatments, such as surgery and transcatheter arterial chemoembolization (TACE) have been applied, in combination with chemotherapy or performed alternatively. However, the clinical utility of local treatment has not been established in LMBC; by contrast, surgery is widely considered to be a useful treatment option in liver metastasis from colorectal cancer (9).Proton beam therapy (PBT) is characterized by precisely delivering a high dose of radiation to the target, while significantly limiting the exposure of regions beyond the target. It is well known that PBT for primary liver cancer achieves excellent local control rates with few adverse effects (10-14). The preliminary outcome of 5 LMBC cases who received PBT during a maximum follow-up period of 8 years in 2012 was previously reported (15). The cases were further followed up and new patients with LMBC who were treated using PBT were included in order to investig...

show abstract

“…However, radiofrequency ablation suffers from high recurrence rates (4); whereas transarterial chemoembolization and selective internal radiation therapy are contraindicated in cases of complete portal vein thrombosis or hepatic insufficiency. Additionally, postembolization syndrome is often observed and the effect on survival has yet to be proven in larger clinical trials (5). These treatments are also not generally suitable for metastases outside the liver (2).…”

mentioning

confidence: 99%

Intraindividual Comparison of Selective Arterial versus Venous 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Kratochwil

Giesel

López-Benítez

et al. 2010

Clinical Cancer Research

View full text Add to dashboard Cite

Lu is accepted for the palliative treatment of unresectable neuroendocrine cancer. However, the optimal route of administration has not been determined. Using positron-emission tomography (PET)-labeled 68 Ga-DOTATOC, we compared selective tumoral uptake on PET/computed tomography (CT) after arterial or venous administration of the agent in patients with gastroenteropancreatic neuroendocrine tumor. Experimental Design: Fifteen patients with neuroendocrine cancer were examined with 68 Ga-DOTA-TOC PET/CT after intravenous (i.v.) and intraarterial (i.a.) administration within 4 weeks of each other and without any intervening therapy. Eleven patients had multifocal metastases, six were considered to have unresectable primary tumor. The intraarterial catheter was placed in the vessel supplying the main tumor burden. The standard uptake value (SUV) was used to compare intratumoral concentrations of 68 Ga-DOTATOC. Results: Compared with i.v. infusion, the i.a. infusion resulted in an increased SUV in 117 of 122 (96%) liver metastases. The average increase in SUV was 3.75-fold higher with i.a. administration. The increase in uptake for the primary tumors was dependent on the selectivity of the catheter placement, resulting in variable increases in SUV after i.a. injection (1.44-to 7.8-fold higher).Conclusions: This study showed that uptake of DOTATOC is commonly several fold higher after selective i.a. administration in comparison with i.v. injection in both the primary tumor as well as in liver metastases of neuroendocrine cancer. Therefore, intraarterial DOTATOC is a promising drug for regionally intensified radiopeptide therapy. Clin Cancer Res; 16(10); 2899-905. ©2010 AACR.There are few effective treatments for unresectable, well differentiated, disseminated gastroenteropancreatic neuroendocrine tumor (GEP-NET). Although the progression rate was slower than with many solid tumors, NETs also showed poor response to conventional chemotherapy with objective response rates in the range of 10% to 36% (1, 2). Antiproliferative therapy with octreotide or IFN could stabilize disease for ∼8 months (mean), as recently shown in the PROMID study (3). However, tumor shrinkage occurs in <10%. NETs commonly metastasize to the liver, and regional treatments such as radiofrequency ablation, transarterial chemoembolization, and selective internal radiation therapy have been used in this setting. However, radiofrequency ablation suffers from high recurrence rates (4); whereas transarterial chemoembolization and selective internal radiation therapy are contraindicated in cases of complete portal vein thrombosis or hepatic insufficiency. Additionally, postembolization syndrome is often observed and the effect on survival has yet to be proven in larger clinical trials (5). These treatments are also not generally suitable for metastases outside the liver (2).Although selective internal radiation therapy provides regional untargeted radiation therapy to the liver, peptides targeting the somatostatin receptor, which is frequently overexpress...

show abstract

Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer

Cited by 55 publications

References 42 publications

Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis

Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis

Follow-up study of liver metastasis from breast cancer treated by proton beam therapy

Intraindividual Comparison of Selective Arterial versus Venous 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Contact Info

Product

Resources

About